- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 849-863 of
1,261 results
1027 Exhibit: Holst 1987
Document
IPR2023-00724, No. 1027 Exhibit - Holst 1987 (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
1084 Exhibit: ICH 2001
Document
IPR2023-00724, No. 1084 Exhibit - ICH 2001 (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
1083 Exhibit: Transfer order
Document
IPR2023-00724, No. 1083 Exhibit - Transfer order (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
1117 Exhibit: Exhibit 1117 Disapproval
Document
IPR2023-00724, No. 1117 Exhibit - Exhibit 1117 Disapproval (P.T.A.B. May. 22, 2024)
|
|
Cite Document
2017 Exhibit: EX2017 Novo Nordisk Company Announcement October 10, 2023
Document
IPR2023-00724, No. 2017 Exhibit - EX2017 Novo Nordisk Company Announcement October 10, 2023 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2368 Exhibit: EX2368 Tomkin, GH, Treatment of type 2 diabetes, lifestyle, GLP1 ag...
Document
IPR2023-00724, No. 2368 Exhibit - EX2368 Tomkin, GH, Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors, World J Diabetes, 2014 Oct 15 55636 650 (P.T.A.B. Jan. 17...
|
|
Cite Document
1174 Exhibit: Exhibit 1174 FDA FAQ
Document
IPR2023-00724, No. 1174 Exhibit - Exhibit 1174 FDA FAQ (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1116 Exhibit: Exhibit 1116 Mounjaro label
Document
IPR2023-00724, No. 1116 Exhibit - Exhibit 1116 Mounjaro label (P.T.A.B. May. 22, 2024)
|
|
Cite Document
2655 Exhibit: EX2655 July 2, 2024 Email Thread Among Counsel for Petitioners My...
Document
IPR2023-00724, No. 2655 Exhibit - EX2655 July 2, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding IPR2023 00724 – Service of draft p...
|
|
Cite Document
2505 Exhibit: EX2505 Novo Nordisk, Financial report for the period 1 January 2020...
Document
IPR2023-00724, No. 2505 Exhibit - EX2505 Novo Nordisk, Financial report for the period 1 January 2020 to 31 December 2020 Feb 3, 2021 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2381 Exhibit: EX2381 Valentine, V, Goldman, J and Shubrook, JH, Rationale for, In...
Document
IPR2023-00724, No. 2381 Exhibit - EX2381 Valentine, V, Goldman, J and Shubrook, JH, Rationale for, Initiation and Titration of the Basal InsulinGLP 1RA Fixed Ratio Combination Products, IDe...
|
|
Cite Document
2474 Exhibit: EX2474 US Food Drug Administration, DrugsFDA, Mounjaro
Document
IPR2023-00724, No. 2474 Exhibit - EX2474 US Food Drug Administration, DrugsFDA, Mounjaro (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2071 Exhibit: EX2071 Claim Construction Order, In re Ozempic Semaglutide Paten...
Document
IPR2023-00724, No. 2071 Exhibit - EX2071 Claim Construction Order, In re Ozempic Semaglutide Patent Litigation, MDL No 22 MD 3038, Dkt No 148 D Del July 25, 2023 (P.T.A.B. Jan. 17, 2024...
|
|
Cite Document
2373 Exhibit: EX2373 Cleveland Clinic, “GLP 1 Agonists,” httpsmyclevelandclinicor...
Document
IPR2023-00724, No. 2373 Exhibit - EX2373 Cleveland Clinic, “GLP 1 Agonists,” httpsmyclevelandclinicorghealthtreatments13901 glp 1 agonists, last reviewed July 3, 2023 (P.T.A.B. Jan. 17, 20...
|
|
Cite Document
2430 Exhibit: EX2430 Oseni® Prescribing Information rev Dec 2017
Document
IPR2023-00724, No. 2430 Exhibit - EX2430 Oseni® Prescribing Information rev Dec 2017 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
